MA52963A - Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation - Google Patents
Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisationInfo
- Publication number
- MA52963A MA52963A MA052963A MA52963A MA52963A MA 52963 A MA52963 A MA 52963A MA 052963 A MA052963 A MA 052963A MA 52963 A MA52963 A MA 52963A MA 52963 A MA52963 A MA 52963A
- Authority
- MA
- Morocco
- Prior art keywords
- procedures
- tyrosine phosphatase
- protein inhibitors
- phosphatase protein
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688226P | 2018-06-21 | 2018-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52963A true MA52963A (fr) | 2021-04-28 |
Family
ID=67254011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052963A MA52963A (fr) | 2018-06-21 | 2019-06-21 | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10954202B2 (fr) |
| EP (1) | EP3810580A1 (fr) |
| JP (2) | JP7217762B2 (fr) |
| KR (2) | KR20230074286A (fr) |
| CN (1) | CN112955438A (fr) |
| AR (1) | AR125425A1 (fr) |
| AU (2) | AU2019290197B2 (fr) |
| BR (1) | BR112020026086A2 (fr) |
| CA (1) | CA3104507A1 (fr) |
| CL (1) | CL2020003316A1 (fr) |
| CO (1) | CO2021000447A2 (fr) |
| CR (1) | CR20210017A (fr) |
| DO (1) | DOP2020000252A (fr) |
| EC (1) | ECSP21003520A (fr) |
| IL (1) | IL279587A (fr) |
| MA (1) | MA52963A (fr) |
| MX (1) | MX2020014223A (fr) |
| PE (1) | PE20210372A1 (fr) |
| PH (1) | PH12020552228A1 (fr) |
| SG (1) | SG11202012820PA (fr) |
| TW (1) | TW202016082A (fr) |
| UY (1) | UY38272A (fr) |
| WO (1) | WO2019246513A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765094A4 (fr) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | Compositions de régulation génique et procédés pour améliorer l'immunothérapie |
| KR20230074822A (ko) * | 2019-03-14 | 2023-05-31 | 칼리코 라이프 사이언시스 엘엘씨 | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 |
| US20230355670A1 (en) * | 2019-12-04 | 2023-11-09 | Monash University | Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors |
| JP2023507774A (ja) * | 2019-12-18 | 2023-02-27 | カリコ ライフ サイエンシーズ エルエルシー | タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法 |
| CA3223322A1 (fr) * | 2021-06-21 | 2022-12-29 | Gesine Kerstin Veits | Composes de degradation et leurs utilisations |
| WO2023086498A1 (fr) * | 2021-11-11 | 2023-05-19 | Calico Life Sciences Llc | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation |
| WO2023086495A1 (fr) * | 2021-11-11 | 2023-05-19 | Calico Life Sciences Llc | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation |
| CN116675653A (zh) * | 2022-07-22 | 2023-09-01 | 中国药科大学 | 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 |
| WO2024059041A1 (fr) * | 2022-09-13 | 2024-03-21 | Kumquat Biosciences, Inc. | N-hétérocycles benzo-fusionnés et leurs utilisations |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DE69212850T2 (de) | 1991-01-15 | 1997-03-06 | Alcon Lab Inc | Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| EP1439834A1 (fr) | 2001-10-30 | 2004-07-28 | Applied Research Systems ARS Holding N.V. | Oxindoles hydrazides modulateurs des proteines tyrosines phosphatases (ptps) |
| ATE534637T1 (de) * | 2002-04-03 | 2011-12-15 | Novartis Ag | 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer |
| GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| WO2008142198A2 (fr) | 2007-05-23 | 2008-11-27 | Valtion Teknillinen Tutkimuskeskus | Procédé pour inhiber ou stimuler l'angiogenèse dans un sujet |
| WO2010008852A2 (fr) | 2008-06-23 | 2010-01-21 | Taiga Biotechnologies, Inc. | Procédés de traitement et procédés de diagnostic d’un trouble immunoprolifératif |
| US9217012B2 (en) | 2009-04-08 | 2015-12-22 | Indiana University Research And Technology Corporation | Inhibitors of protein tyrosine phosphatases |
| WO2011057331A1 (fr) | 2009-11-11 | 2011-05-19 | Monash University | Procédé de traitement de l'obésité |
| WO2011094806A1 (fr) | 2010-02-03 | 2011-08-11 | Monash University | Dosage de diagnostic et de pronostic pour le cancer du sein |
| WO2015127548A1 (fr) | 2014-02-28 | 2015-09-03 | The Royal Institution For The Advancement Of Learning / Mcgill University | Inhibiteurs de tc-ptp en tant qu'activateurs d'apc pour l'immunothérapie |
| US20170224731A1 (en) | 2014-06-10 | 2017-08-10 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| US20180325925A1 (en) | 2015-11-06 | 2018-11-15 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor |
| WO2017078499A2 (fr) | 2015-11-06 | 2017-05-11 | 경북대학교 산학협력단 | Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase |
| WO2018148378A1 (fr) | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulation de biomarqueurs pour accroître l'immunité antitumorale et améliorer l'efficacité d'une immunothérapie anticancéreuse |
| WO2018227248A1 (fr) | 2017-06-13 | 2018-12-20 | Monash University | Méthodes et compositions pour le traitement de l'obésité |
| US11597739B2 (en) | 2017-08-24 | 2023-03-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP) |
-
2019
- 2019-06-21 WO PCT/US2019/038459 patent/WO2019246513A1/fr unknown
- 2019-06-21 CN CN201980054332.9A patent/CN112955438A/zh active Pending
- 2019-06-21 TW TW108121816A patent/TW202016082A/zh unknown
- 2019-06-21 MA MA052963A patent/MA52963A/fr unknown
- 2019-06-21 BR BR112020026086-0A patent/BR112020026086A2/pt unknown
- 2019-06-21 KR KR1020237016153A patent/KR20230074286A/ko active Application Filing
- 2019-06-21 CR CR20210017A patent/CR20210017A/es unknown
- 2019-06-21 EP EP19739482.8A patent/EP3810580A1/fr active Pending
- 2019-06-21 KR KR1020217001743A patent/KR102533477B1/ko active IP Right Grant
- 2019-06-21 MX MX2020014223A patent/MX2020014223A/es unknown
- 2019-06-21 UY UY0001038272A patent/UY38272A/es unknown
- 2019-06-21 AR ARP190101729A patent/AR125425A1/es unknown
- 2019-06-21 AU AU2019290197A patent/AU2019290197B2/en active Active
- 2019-06-21 SG SG11202012820PA patent/SG11202012820PA/en unknown
- 2019-06-21 JP JP2020571382A patent/JP7217762B2/ja active Active
- 2019-06-21 PE PE2020002131A patent/PE20210372A1/es unknown
- 2019-06-21 CA CA3104507A patent/CA3104507A1/fr active Pending
-
2020
- 2020-09-18 US US17/025,644 patent/US10954202B2/en active Active
- 2020-12-20 IL IL279587A patent/IL279587A/en unknown
- 2020-12-21 DO DO2020000252A patent/DOP2020000252A/es unknown
- 2020-12-21 PH PH12020552228A patent/PH12020552228A1/en unknown
- 2020-12-21 CL CL2020003316A patent/CL2020003316A1/es unknown
-
2021
- 2021-01-18 EC ECSENADI20213520A patent/ECSP21003520A/es unknown
- 2021-01-19 CO CONC2021/0000447A patent/CO2021000447A2/es unknown
-
2023
- 2023-01-24 JP JP2023008491A patent/JP2023055771A/ja active Pending
- 2023-11-10 AU AU2023263567A patent/AU2023263567A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7217762B2 (ja) | 2023-02-03 |
| UY38272A (es) | 2019-12-31 |
| PE20210372A1 (es) | 2021-02-26 |
| US10954202B2 (en) | 2021-03-23 |
| AU2019290197B2 (en) | 2023-08-24 |
| US20210009542A1 (en) | 2021-01-14 |
| ECSP21003520A (es) | 2021-02-26 |
| EP3810580A1 (fr) | 2021-04-28 |
| AU2023263567A1 (en) | 2023-11-30 |
| IL279587A (en) | 2021-03-01 |
| JP2021530443A (ja) | 2021-11-11 |
| CR20210017A (es) | 2021-11-03 |
| AU2019290197A1 (en) | 2021-01-21 |
| SG11202012820PA (en) | 2021-01-28 |
| JP2023055771A (ja) | 2023-04-18 |
| KR102533477B1 (ko) | 2023-05-18 |
| KR20230074286A (ko) | 2023-05-26 |
| BR112020026086A2 (pt) | 2021-03-23 |
| AR125425A1 (es) | 2023-07-19 |
| KR20210034589A (ko) | 2021-03-30 |
| CN112955438A (zh) | 2021-06-11 |
| PH12020552228A1 (en) | 2021-08-16 |
| MX2020014223A (es) | 2021-06-23 |
| DOP2020000252A (es) | 2021-07-15 |
| CO2021000447A2 (es) | 2021-07-19 |
| CA3104507A1 (fr) | 2019-12-26 |
| WO2019246513A1 (fr) | 2019-12-26 |
| CL2020003316A1 (es) | 2021-06-11 |
| TW202016082A (zh) | 2020-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA55301A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| MA55511A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA52781A (fr) | Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| MA50912A (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés |